Cadila Health on May 14 said it is “on track” for a May-end submission of its COVID-19 vaccine to the Indian drug regulator, CNBC-TV18 reported.
As per the report, Cadila will file for an emergency use authorisation (EUA) after it has submitted its vaccine to the Drugs Controller General of India (DCGI) and is aiming to supply 5 crore doses of its candidate to India by year-end.
Follow our LIVE Updates on the coronavirus pandemic here
This is in line with the Centre’s announcement of making available more than two billion doses of COVID-19 vaccines in India, between August and December 2021.
This was stated by Niti Aayog member Dr VK Paul, who further said that the bulk of these doses – 750 million (75 crore) doses would comprise of Covishield, which is being produced by Pune-based Serum Institute of India (SII); while another 550 million (55 crore) doses of Covaxin, made by Hyderabad's Bharat Biotech, would also be available.
Below is a breakdown of the expected pipeline:
| Vaccine | Production/Availability (August-December 2021) | India Manufacturer |
| Covishield | 75 crore | Serum Institute of India |
| Covaxin | 55 crore | Bharat Biotech |
| Bio E sub vaccine | 30 crore | Biological E |
| Zydus Cadila DNA vaccine | 5 crore | Zydus Cadila |
| Novavax vaccine | 20 crore | Serum Institute of India |
| BB Nasal vaccine | 10 crore | -- |
| Genova mRNA vaccine | 6 crore | -- |
| Sputnik vaccine | 15.6 crore | Dr Reddy’s Laboratory |
| TOTAL | 216 crore | |
| Source: PIB/Twitter |
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
